Qlife Holding AB loses arbitration proceedings against Aidian

On 13 March 2023, Qlife Holding AB (“Qlife” or the “Company”) announced that Aidian Oy had initiated arbitration proceedings against Qlife’s wholly owned subsidiary Qlife ApS regarding payment of unpaid invoices for various products and services. Today, Qlife has received the judgment in the arbitration proceedings. Qlife ApS has been ordered to pay approximately MEUR 0.80 to Aidian for its claim together with a contractually agreed annual penal interest of 10.00 per cent per annum from the due dates onward until payment, and approximately MEUR 0.26 to Aidian for its legal fees together with penal interests according to Finish law as of 30 days from the date of the arbitral award until full payment. In addition, Qlife Aps shall pay approximately MEUR 0.07 for the fees and costs for the arbitrator as well as administrative costs related to the arbitration proceedings.

This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 24-06-2024 12:44 CET

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34

Qlife is a Swedish company based in Helsingborg, which develops and markets an innovative medical technology platform, Egoo.Health (”Egoo”), with the goal of giving people access to clinical biomarker data when testing at home. The company is listed on the Nasdaq First North Growth Market (ticker: QLIFE). G&W Fondkommission is the Company’s Certified Adviser. For additional information, please visit www.qlifeholding.com.